ERBB2 and gastric cancer: We found that T-DXd inhibited cell proliferation of not only trastuzumab-sensitive HER2-positive GC cells (NCI-N87 and OE19 cells) but also trastuzumab-resistant HER2-positive GC cells (MKN7 cells) (Fig. 1C).